S19-501C Composition of the Treatment of X-linked Chronic Granulomatous Disease (X-CGD) Deficiency in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system. Mara Pavel-Dinu Matthew Porteus